tradingkey.logo

Wave Life Sciences Plans To Accelerate Regulatory Engagement With Full Control Of WVE-006

ReutersFeb 2, 2026 1:22 PM

- WAVE Life Sciences Ltd WVE.O:

  • WAVE LIFE SCIENCES ANNOUNCES PLANS TO ACCELERATE REGULATORY ENGAGEMENT WITH FULL CONTROL OF WVE-006 FOR ALPHA-1 ANTITRYPSIN DEFICIENCY

  • WAVE LIFE SCIENCES LTD: PLANS TO ENGAGE FDA ON POTENTIAL ACCELERATED APPROVAL PATHWAY FOR WVE-006, WITH REGULATORY FEEDBACK ANTICIPATED MID-2026

  • WAVE LIFE SCIENCES LTD - DATA FROM 400 MG COHORT ON TRACK FOR Q1 2026

  • WAVE LIFE SCIENCES LTD: DATA FROM 600 MG SINGLE AND MULTIDOSE COHORTS ARE EXPECTED IN 2026

  • WAVE LIFE SCIENCES LTD - EXPECTS CASH RUNWAY INTO THIRD QUARTER OF 2028

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI